TXMD News and Press, TherapeuticsMD Inc. From 03/07/22

GoodRx has agreed to acquire vitaCare for $150 million in cash, with an additional $7 million consideration contingent upon vitaCare’s financial performance through 2023 TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an inno...

-Executive Management to Host Conference Call on March 10, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its fourth q...

Shares of leading healthcare company TherapeuticsMD (TXMD) declined by 72.9% in price last year as the company suffered losses and negative cash flows. In addition, given worries surrounding the stock's non-compliance with Nasdaq's listing rules, is it wise to bet on the stock now? Read on, l...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Let’s start off the day right with a look into the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com Loads of penny stocks are on the move today and we&#...

TherapeuticsMD (NASDAQ:TXMD) announced that the FDA had not approved the revisions sought by the company to certain manufacturing specifications related to ANNOVERA, a ring-shaped contraceptive marketed by the company for women. In a Supplemental New Drug Application ((sNDA)), TherapeuticsMD ...

- FDA determined that it could not approve proposed revisions to the manufacturing testing limits requested through the Supplemental New Drug Application (sNDA) - - FDA provided recommendations and requested additional information to address the issues - - The Company will continue ...

TherapeuticsMD (NASDAQ:TXMD) announces the settlement of the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals (NYSE:AMRX). TXMD shares up 2% premarket at $0.45. As part of the settlement, TXMD granted to Amneal a license to commercialize latter's ge...

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of...

During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...

Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q3 2021 Earnings Call Nov 11, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call Transcript